Siddhartha Yadav, Associate Professor of Oncology and Consultant Medical Oncologist at the Mayo Clinic, shared a post on LinkedIn:
“Wrapping up a highly productive San Antonio Breast Cancer Symposium. I was only here for a day, but accomplished more than I could have imagined: Two oral spotlight presentations and two posters, all focused on germline pathogenic variant (PV) carriers. Many thanks to all co-investigators, collaborators, patients and patient advocates who made this possible.
A major highlight was watching my mentor, Fergus J. Couch, PhD, receive the prestigious Brinker Award from the Komen Foundation. He is a giant in the field, and the recognition is truly deserved.
Below is a summary of the work we presented at SABCS. Feel free to reach out if you’d like more details:
1. PD4-04: Results from the GENRE-2 clinical trial show that polygenic risk scores (PRS) may help shift clinically meaningful risk categories for carriers of moderate-risk gene PVs such as ATM or CHEK2, but not for high-risk genes like BRCA1/2.
2. PD4-08: Real-world data from more than 35,000 women with metastatic HER2-negative breast cancer reveal that approximately 40% have not received germline or tumor BRCA testing. We need to do better.
3. PS2-08-25: Evaluation of Breast Cancer Index (BCI) in estrogen receptor–positive tumors of germline PV carriers shows that more than two-thirds of BRCA1 carriers have a high risk of recurrence and a high likelihood of benefiting from extended endocrine therapy.
4. PS02-02-08: Real-world treatment data from more than 800 BRCA1 PV carriers with metastatic HER2-negative breast cancer suggest that PARP inhibitors are underutilized in hormone receptor–positive disease compared to triple-negative breast cancer, and nearly half of all patients did not receive a PARP inhibitor at any point.”
You Can Also Read:
15 Posts Not to Miss from SABCS 2025, Part 1
20 Posts Not to Miss from SABCS 2025, Part 2
